Experts weigh first-line EGFR lung cancer options, from osimertinib alone to combos, with guidance for brain mets and TP53 high-risk patients.

Explore how brain metastases and TP53 co-mutations shape EGFR-mutant NSCLC first-line care, including intracranial control, radiation sequencing, and key trial insights.

In this segment, the panel digs into the new data from the FLAURA-2 trial being presented at this year's World Conference on Lung Cancer, covering both a biomarker analysis examining TP53 co-mutation and acquired resistance mechanisms and an extended safety follow-up.

In this segment, the panel discusses the eight-year overall survival update from the adjuvant TKI trial being presented at the presidential session of this year's World Conference on Lung Cancer.

In this segment, the panel addresses what happens when a patient progresses on frontline EGFR-directed therapy, starting with how to approach repeat molecular profiling and what resistance mechanisms to look for.

In this segment, the panel focuses on MET alterations as one of the most consistently actionable resistance mechanisms in EGFR-mutant non-small cell lung cancer and discusses the first randomized trial data now available in this setting.

In this segment, the panel turns to EGFR exon 20 insertion mutations, a subgroup that has historically been underserved by the major advances in the classical EGFR mutation space and that requires comprehensive testing to identify reliably.

In this final segment, the panel reflects on where the field stands and what they are most closely watching as the treatment landscape for EGFR-mutant non-small cell lung cancer continues to evolve.